83 related articles for article (PubMed ID: 26503812)
1. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
López-Knowles E; Wilkerson PM; Ribas R; Anderson H; Mackay A; Ghazoui Z; Rani A; Osin P; Nerurkar A; Renshaw L; Larionov A; Miller WR; Dixon JM; Reis-Filho JS; Dunbier AK; Martin LA; Dowsett M
Breast Cancer Res; 2015 Mar; 17(1):35. PubMed ID: 25888249
[TBL] [Abstract][Full Text] [Related]
2. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
Liang Y; Gersch CL; Lehman J; Henry NL; Smith KL; Rae JM; Stearns V; Hertz DL
Pharmacogenet Genomics; 2024 Jun; 34(4):126-129. PubMed ID: 38359166
[TBL] [Abstract][Full Text] [Related]
3. Preemptively Precise: Returning and Updating Pharmacogenetic Test Results to Realize the Benefits of Preemptive Testing.
Haidar CE; Relling MV; Hoffman JM
Clin Pharmacol Ther; 2019 Nov; 106(5):942-944. PubMed ID: 31520409
[No Abstract] [Full Text] [Related]
4. An Expiration Date for Pharmacogenetic Test Results and Prescribing Guidance?
Hernandez-Martinez V; Duconge J; Ruaño G
J Appl Lab Med; 2023 Jul; 8(4):826-830. PubMed ID: 37228092
[No Abstract] [Full Text] [Related]
5. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
6. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
7. Integrated Bioinformatics, Environmental Epidemiologic and Genomic Approaches to Identify Environmental and Molecular Links between Endometriosis and Breast Cancer.
Roy D; Morgan M; Yoo C; Deoraj A; Roy S; Yadav VK; Garoub M; Assaggaf H; Doke M
Int J Mol Sci; 2015 Oct; 16(10):25285-322. PubMed ID: 26512648
[TBL] [Abstract][Full Text] [Related]
8. Roles of ABCC1 and ABCC4 in Proliferation and Migration of Breast Cancer Cell Lines.
Low FG; Shabir K; Brown JE; Bill RM; Rothnie AJ
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081264
[TBL] [Abstract][Full Text] [Related]
9. The plasma peptides of breast versus ovarian cancer.
Dufresne J; Bowden P; Thavarajah T; Florentinus-Mefailoski A; Chen ZZ; Tucholska M; Norzin T; Ho MT; Phan M; Mohamed N; Ravandi A; Stanton E; Slutsky AS; Dos Santos CC; Romaschin A; Marshall JC; Addison C; Malone S; Heyland D; Scheltens P; Killestein J; Teunissen C; Diamandis EP; Siu KWM; Marshall JG
Clin Proteomics; 2019; 16():43. PubMed ID: 31889940
[TBL] [Abstract][Full Text] [Related]
10. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
[TBL] [Abstract][Full Text] [Related]
11. Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis.
Zhu Y; Koleck TA; Bender CM; Conley YP
Biol Res Nurs; 2020 Apr; 22(2):263-276. PubMed ID: 31847542
[TBL] [Abstract][Full Text] [Related]
12. The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.
Liu X; Low SK; Boddy AV
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):851-63. PubMed ID: 27253864
[TBL] [Abstract][Full Text] [Related]
13. Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.
Rumiato E; Brunello A; Ahcene-Djaballah S; Borgato L; Gusella M; Menon D; Pasini F; Amadori A; Saggioro D; Zagonel V
Pharmacogenomics J; 2016 Nov; 16(6):525-529. PubMed ID: 26503812
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of aromatase inhibitors.
Hadfield KD; Newman WG
Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
